The prolonged-release Nifedipine formulation is commonly used as part of a therapeutic regimen to provide continuous, stable support in the management of chronic cardiovascular and vascular conditions, focusing on therapeutic benefit and symptom control. Its primary therapeutic areas include hypertension and angina. This medication is relevant for easing the burden of recurring ischemic chest discomfort, provides support in managing symptom clusters associated with Angina Pectoris (both chronic stable and vasospastic types), and is applied in addressing symptoms related to peripheral vascular disorders like Raynaud's Phenomenon.

---

Key Therapeutic Focus

This medication is commonly used to help manage persistently high blood pressure in adults and supports the patient during difficult episodes by easing distress related to exertion and vasospastic events. The medication is applied to address symptoms related to systemic imbalance and supports functional stability.

“The therapeutic support helps manage symptoms that interfere with daily comfort and may assist with maintaining functional stability.”

Quick Fact: Relief for Vascular Discomfort The sustained-release formulation is applied in scenarios requiring support for recurrent or episodic manifestations, assisting with managing symptoms related to heightened physiological activity and increased physiological stress.

Eligibility Map: Who Can and Cannot Use Adalat Retard

Official regulatory documents establish strict criteria regarding which populations can and cannot use Adalat Retard (Nifedipine prolonged-release).

Classification	Population or Condition
Contraindicated	Cardiogenic shock, unstable angina, or use within one month of a heart attack [1.1, 1.3].
Contraindicated	Known hypersensitivity to Nifedipine or other dihydropyridines [1.1].
Contraindicated	History of gastro-intestinal obstruction or having a Kock pouch (due to the prolonged-release design) [1.1].
Contraindicated	Concomitant therapy with Rifampicin [1.1].
Not Recommended	Children and adolescents (Safety and efficacy are not established) [1.2, 1.7].
Not Recommended	Pregnant or breastfeeding women (General use is not recommended, though restricted use may occur for severe hypertension) [1.1, 3.6].
Conditional Use	Patients with impaired liver function require careful monitoring and may need a dose reduction [1.2, 3.1].
Conditional Use	Patients with severe hypotension (systolic BP < 90 mmHg) or poor cardiac reserve require caution [1.1, 1.3].

The eligibility profile is defined by absolute contraindications related to cardiac stability and the drug's extended-release physical form, combined with official non-recommendations for vulnerable age groups and pregnant/lactating populations.

Adalat Retard Interactions with other medicines and products

The interaction profile of this medication is heavily influenced by the Cytochrome P450 3A4 (CYP3A4) enzyme system, which metabolizes the active ingredient Nifedipine. Interaction statements are derived strictly from authoritative government regulatory documents.

---

Interaction-Related Restrictions

Classification	Interacting Agent	Official Regulatory Statement
Contraindicated	Rifampicin	Use is formally prohibited due to strong CYP3A4 enzyme induction leading to a severe reduction in Nifedipine plasma concentrations and efficacy.
Avoidance Required	Grapefruit Juice	Must be avoided because it inhibits CYP3A4, which can lead to a documented increase (up to 2-fold) in Nifedipine plasma levels.
Not Recommended	St John's Wort	This herbal product is a CYP3A4 inducer that is documented to weaken Nifedipine's effects by increasing its clearance.

---

Official Interaction Statements

• Exposure Alteration: Co-administration with other CYP3A4 inducers (e.g., Phenytoin, Carbamazepine, Phenobarbital) is documented to reduce Nifedipine's bioavailability, weakening its therapeutic response [1.2, 2.6]. Conversely, CYP3A4 inhibitors (e.g., certain Macrolide Antibiotics, Azole Antimycotics, Anti-HIV Protease Inhibitors) can increase Nifedipine plasma concentrations [1.3].
• Pharmacodynamic Effects: Use with other antihypertensive agents (e.g., Beta-blockers) is associated with an additive blood pressure lowering effect, which may result in postural hypotension [2.7].
• Clearance-Altering Agents: Nifedipine may affect the clearance of co-administered drugs like Digoxin and Tacrolimus, causing officially documented increased plasma levels of these agents [1.4, 1.5].
• Population Note: Regulatory documents note that the effects and clearance of Nifedipine may be increased in patients with hepatic impairment and that diabetic patients may require an adjustment of their blood sugar control regimen [1.1, 1.7].

The mechanism of Nifedipine (the active ingredient) is defined by its precise interaction with specific molecular targets, which result in physiological changes in the circulatory system.

---

Targeted Blockade of L-Type Calcium Channels

Nifedipine functions as an inhibitor with a high degree of selectivity for the L-type Voltage-Gated Calcium Channels (L-VGCCs), which are vital for controlling muscle contraction in the walls of blood vessels. By binding to these channels, the drug physically blocks the entry of extracellular calcium ions into the cell, thereby initiating the key mechanistic cascade.

---

Systemic Relaxation of Vascular Smooth Muscle

The reduction of intracellular calcium concentration inhibits the molecular steps necessary for the smooth muscle fibers to contract. This cellular-level relaxation causes a systemic effect: the widening of the arteries (vasodilation) throughout the body. This mechanism causes a reduction in the total peripheral vascular resistance (afterload), a physiological load against which the heart works to eject blood.

---

Sustained Modulation of Circulatory Resistance

The prolonged-release formulation ensures a slow, steady delivery of the active ingredient, maintaining a consistent level of channel blockade over an extended period. This design, by providing slow delivery, modulates the baroreceptor reflex—the body's counter-regulatory response to rapid vasodilation—which contributes to a more consistent reduction of systemic blood pressure and stable coronary vasodilation.

How to use Adalat Retard

This section outlines the standardized protocol for the administration of Adalat Retard, based strictly on prescribing information. The medication is an oral prolonged-release tablet and its correct use is governed by a precise set of administration rules and dosage schedules.

---

Administration Scope

Feature	Official Instruction
Route of Administration	Oral administration only.
Dosing Schedule	Initial dose is typically 10 mg or 20 mg twice daily for the Retard formulation, with a maximum daily dose of 60 mg. Dosing is introduced gradually and titrated to individual requirement.
Frequency and Timing	Taken twice daily, ensuring a minimum interval of 4 hours between doses.
Intake Conditions	May be taken irrespective of meal times (with or without food). Must not be taken with grapefruit juice or grapefruit products.
Physical Handling	Tablet must be swallowed whole with water. It is forbidden to chew, crush, or break up the tablet.

---

Population-Specific Rules

Patient Group	Adjustment Requirement
Hepatic Impairment	Requires careful monitoring and a dose reduction; therapy should start at the lowest available dose.
Renal Impairment	No dosage adjustment is required.
Children (Under 18)	Use is not recommended baker.

---

Protocol Structure

The official use protocol is structured around maintaining stable drug concentrations over a continuous period. The adherence to the twice-daily frequency and the minimum 4-hour interval is essential to the therapeutic design of the prolonged-release formulation. Treatment is generally long-term, and if discontinuation is necessary, the medication must be discontinued gradually under supervision. The procedural structure mandates swallowing the tablet whole to ensure the intended slow release, thus preventing rapid absorption.

Research Evidence / Overview of Studies for Adalat Retard

This section provides a transparent summary of the clinical research conducted on Adalat Retard (Nifedipine Prolonged-Release). This overview describes the types of studies available and what they monitored, without offering any clinical advice or making claims about individual outcomes. The findings described reflect group patterns observed in research, not personal predictions.

---

Evidence for Use in Chronic Stable Angina Pectoris

Research exploring the potential use of Nifedipine prolonged-release in the context of symptoms associated with chronic stable angina includes Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses. These studies focused on understanding how symptoms change over time.

Researchers typically examined outcomes describing perceived discomfort, such as the measured frequency and severity of angina attacks, and outcomes reflecting daily functioning, like exercise capacity. Research reported patterns observed in the studies related to the measured frequency of attacks and the patients' use of rescue medication.

Evidence for Use in High Blood Pressure (Hypertension)

Nifedipine prolonged-release was studied for its use in an extensive body of research for high blood pressure (hypertension). This includes large-scale Randomized Controlled Trials (RCTs) examining its use, as well as long-term observational studies.

The research primarily monitored outcomes related to systemic or functional imbalance, specifically the change in Systolic and Diastolic Blood Pressure (BP). Findings described patterns related to changes measured in mean BP across various adult groups. Studies also described how blood pressure measurements evolved over defined time intervals.

---

What is Still Uncertain About Adalat Retard Research

A transparent review of the evidence highlights what is known and what is still uncertain about the research base. Evidence quality varies across studies, particularly in the small-scale symptom control trials for conditions like Raynaud's Phenomenon where follow-up durations were limited. For the hypertension and angina indications, comparative evidence for major outcome tracking is often drawn from the broad class of calcium channel blockers. This means long-term effects are not fully established for the specific Nifedipine PR formulation regarding all composite outcomes.

Key Studies & References

1. Anti-anginal and anti-ischaemic effects of long-acting nifedipine in patients with chronic stable angina: a systematic review and meta-analysis

Common questions about Adalat Retard (FAQ)

---

Q: What are the signs of a serious or rare side effect associated with Adalat Retard?

Serious reactions documented in regulatory texts include severe hypotension (low blood pressure), an increase in the frequency or severity of existing angina (chest pain), and angioedema (a severe allergic reaction involving swelling of the face, lips, tongue, or throat). This classification establishes the recognized risks associated with the medicine.

---

Q: Can people with diabetes use Adalat Retard?

The use of this medication in individuals with diabetes is addressed in official product information, which indicates that it requires careful oversight. Regulatory documents state that patients with diabetes may require an adjustment to their existing blood sugar control regimen while taking this medicine.

---

Q: What happens if Adalat Retard is stopped suddenly?

Official information advises that treatment with Adalat Retard should be discontinued gradually under the supervision of a healthcare professional. The procedural structure of treatment mandates this protocol. The medication must not be stopped suddenly.

---

Q: Does Adalat Retard cause dizziness or light-headedness, and when is this most likely to occur?

Dizziness or light-headedness is listed as an uncommon side effect of this medication. Official information indicates these effects are particularly noted at the start of treatment, upon a change in medication, or when taken in combination with alcohol.

---

Q: Why are people often told to avoid driving when first starting Adalat Retard?

Regulatory documents state that reactions such as dizziness can potentially impair the ability to drive or operate machinery. This is a common precaution for medicines that cause changes in blood pressure or light-headedness, particularly when the treatment is first initiated.

---

Q: Is it normal to see the tablet shell in the stool after taking Adalat Retard?

Official product information for this prolonged-release dosage form notes that the outer membrane of the tablet is not digested. Because the outer membrane is not digested, what appears to be the complete tablet or the empty shell may be seen in the stool.

---

Q: Are there special considerations for elderly patients taking Adalat Retard?

Regulatory information indicates that the body handles the drug differently (pharmacokinetics) in elderly patients. Official prescribing information notes that lower maintenance doses may be required for this population compared to younger adults.

---

Q: Is it true that Adalat Retard can cause the need to urinate more frequently?

Official product information lists an increase in the need to pass water (urinate) as an uncommon side effect of the medication. This is a documented adverse reaction that patients should be aware of.

---

Q: Is alcohol consumption restricted while using Adalat Retard?

Yes, official product information recommends that alcohol consumption should be avoided while using this medication. Alcohol may potentially worsen a person’s underlying condition or increase the occurrence of side effects, such as dizziness.

---

Q: Does Adalat Retard have any known effect on a person's mood or emotional state?

Effects related to a person's mood or emotional state are documented, though classified as uncommon. Specifically, regulatory documents list anxiety or nervousness as uncommon side effects of this medication.

---

Q: What should a patient do if they miss a scheduled dose of Adalat Retard?

If a dose is missed and it is less than four hours until the next scheduled dose (for twice-daily dosing), official guidance is to leave out the missed dose. Patients are advised not to take two doses to make up for a forgotten one.

How to Store and Dispose of Adalat Retard?

Storing this medicine according to official requirements is essential to maintain its stability and effectiveness. The product must be stored at a temperature not above 30°C.

To ensure product stability, the medication must be protected from strong light. For this reason, it is necessary to keep the medicine in the original container until use.

Disposal Requirements

When disposing of Adalat Retard that is no longer needed or has expired, it should not be discarded via household waste or wastewater. Official guidance instructs individuals to ask a pharmacist how to dispose of unused medicines. This measure helps ensure proper handling and is taken to protect the environment.